Baxter International Inc Stock News

Baxter's (BAX) ST Set is expected to improve treatments in an acute care environment.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2022 financial results on Thursday, April 28,

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.

In December 2021, Baxter International Inc (NYSE: BAX ) issued an urgent safety communication about an issue with some of its Spectrum infusion pumps. The FDA has identified this as a Class I recall , the most serious type of recall. The recall pertains to Baxter''s Spectrum V8 and Spectrum IQ infusion pumps used in clinical settings to deliver controlled amounts of fluids such as pharmaceutical drugs, blood & blood products, and … Full story available on Benzinga.com

Baxter's (BAX) latest strategic partnership with Digital Diagnostics is expected to expand its connected care diagnostics portfolio.

IHI: A Standout Performer With Equally Strong Future Growth Prospects

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Barclays Global Healthcare Conference on Thursday, March 17, 2022. Jay Saccaro, Bax

Baxter International Inc. with ticker code (BAX) now have 14 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 105 and 86 calculating the mean target price we have 95.86. Now with the previous closing price of 84.65 this would imply there is a potential upside of 13.2%. There is a 50 day moving average of 85.73 and the 200 moving average now moves to 81.33. The company has a market cap of $43,190m. You can visit the company''s website by visiting: https://www.baxter.com [stock_market_widget type="chart" template="basic" color="green" assets=BAX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $48,909m based on the market concensus. Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

DUBLIN--(BUSINESS WIRE)--The "Regenerative Medicine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com''s offering. The global regenerative medicine market reached a value of US$ 14.78 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 50.44 Billion by 2027, exhibiting a CAGR of 22.6% during 2022-2027. Companies Mentioned Allergan PLC (AbbVie Inc.) Amgen Inc. Baxter International In

The U.S. Securities and Exchange Commission has levied an $18M fine against Baxter International (BAX) for engaging in what it described as accounting improprieties.

Tuesday''s top analyst upgrades and downgrades included Advanced Micro Devices, Baxter International, Constellation Energy, CrowdStrike, Datadog, Nutrien, Sandstorm Gold, SentinelOne and Zhihu.

I wrote about Baxter a few months back, considering the company a conservative "BUY" based on good fundamentals and M&A. While the company hasn't outperformed, it hasn't dropped either. So far, realiz

Baxter International Inc. found using ticker (BAX) now have 16 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 110 and 88 and has a mean target at 97. Given that the stocks previous close was at 82.8 this indicates there is a potential upside of 17.1%. The 50 day MA is 85.45 and the 200 day moving average is 81.33. The company has a market capitalisation of $41,232m. Company Website: https://www.baxter.com [stock_market_widget type="chart" template="basic" color="green" assets=BAX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $48,303m based on the market concensus. Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Riding The Stock Waves: Update On The Medical Devices Sector